Conference News

Elotuzumab Regimen Active in High-risk Smoldering Multiple Myeloma

Elotuzumab Regimen Active in High-risk Smoldering Multiple Myeloma

By

A study presented at 2016 ASH annual meeting demonstrated that the combination of elotuzumab, lenalidomide, and dexamethasone has potential in patients with high-risk smoldering multiple myeloma, a population that would otherwise not receive treatment.

Second Round of Treatment Does Not Improve PFS in Multiple Myeloma

Second Round of Treatment Does Not Improve PFS in Multiple Myeloma

By

A study presented at the 2016 Annual Meeting of ASH assessed the impact of additional interventions on progression-free survival in patients with multiple myeloma.

Osimertinib New Standard of Care for T790M+ Advanced NSCLC

Osimertinib New Standard of Care for T790M+ Advanced NSCLC

By

A study presented at the World Conference on Lung Cancer compared progression-free survival after treatment with osimertinib with that of platinum therapy plus pemetrexed in a select group of patients with T790M-positive advanced NSCLC.

Scalp-cooling Device To Reduce Chemotherapy-related Alopecia

Scalp-cooling Device To Reduce Chemotherapy-related Alopecia

By

A new system appears efficacious in preventing chemotherapy-related alopecia in women with breast cancer, according to a study presented at SABCS 2016.

Menopause-related Nausea/Vomiting and Headaches Effects Tamoxifen Adherence

Menopause-related Nausea/Vomiting and Headaches Effects Tamoxifen Adherence

By

Women who experienced menopause-related side effects were significantly less likely to adhere to their assigned tamoxifen therapy.

Community Breast Navigation Program Improved Breast Screening Rates in Underserved African American and Latino Women

Community Breast Navigation Program Improved Breast Screening Rates in Underserved African American and Latino Women

By

A community breast navigation program successfully increased mammogram screening rates among African American and Latino women, according to a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).

Live-streamed Videos Address End-of-Life Planning, Decision-making

Live-streamed Videos Address End-of-Life Planning, Decision-making

By

Live-streamed videos are a novel and forward-thinking approach for individuals to learn about end-of-life (EOL) planning and decision-making, according a study presented at the 2016 San Antonio Breast Cancer Symposium.

Metastatic Disease Linked to Patients Reporting Diminished QoL

Metastatic Disease Linked to Patients Reporting Diminished QoL

By

Patients with metastatic breast cancer have significantly diminished quality of life (QoL) compared with those without metastatic disease and those without breast cancer, a study presented at the 2016 San Antonio Breast Cancer Symposium.

History of Bilateral Salpingo-oophorectomy, Hormone Replacement Therapy Are Predictive of Breast Density at Cancer Diagnosis

History of Bilateral Salpingo-oophorectomy, Hormone Replacement Therapy Are Predictive of Breast Density at Cancer Diagnosis

By

A history of surgical menopause and were receiving hormone replacement therapy are a factor in breast density, according to a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).

Mammographically Occult Contralateral Breast Cancer Detection is Effective With Preoperative MRI

Mammographically Occult Contralateral Breast Cancer Detection is Effective With Preoperative MRI

By

Study data presented at SABCS 2016 indicates that preoperative MRI is effective for detecting mammographically occult, early-stage, hormone receptor (HR)-positive contralateral breast cancer (CBC) in older patients.

Clinical Breast Examination Superior to MRI for Predicting pCR in HER2+ Breast Cancer

Clinical Breast Examination Superior to MRI for Predicting pCR in HER2+ Breast Cancer

By

Clinical breast examination (CBE) is superior to MRI for predicting pathologic complete response (pCR) in women with HER2-positive breast cancer, a study presented at the 2016 San Antonio Breast Cancer Symposium indicates.

Genomic Features Predictive of Response to Trastuzumab-Containing Therapy

Genomic Features Predictive of Response to Trastuzumab-Containing Therapy

By

Research presented at SABCS 2016 identified biomarkers predictive of response to trastuzumab-containing therapies in patients with HER2-positive breast cancer.

Video Tool to Increase Breast Cancer Clinical Trial Participation Among Black Women

Video Tool to Increase Breast Cancer Clinical Trial Participation Among Black Women

By

A new tool may show promise for improving clinical trial participation among black women with breast cancer, according to a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).

No Difference Between RA Seed Localization and Wire Guided Localization

No Difference Between RA Seed Localization and Wire Guided Localization

By

Results of a comparison study of radioactive seed localization and wire guided localization in patients with nonpalpable invasive breast cancer or DCIS were presented at SABCS 2016.

Dual HER2 Blockade With an AI Effective in Advanced Breast Cancer

Dual HER2 Blockade With an AI Effective in Advanced Breast Cancer

By

Patients with HER2-positive, HR-positive advanced breast cancer experience significantly improved progression-free survival when pertuzumab is added to first-line trastuzumab and an AI compared with trastuzumab and an AI alone, according to study findings presented at SABCS 2016.

BRD4 Inhibitor May Enhance Sensitivity to Endocrine Therapies

BRD4 Inhibitor May Enhance Sensitivity to Endocrine Therapies

By

A novel bromodomain-containing protein 4 inhibitor demonstrated antitumor activity in both endocrine-sensitive and endocrine-resistance breast cancer models, according to a study presented at SABCS 2016.

Loperamide Regimen May Reduce Diarrhea in Neratinib-treated Patients

Loperamide Regimen May Reduce Diarrhea in Neratinib-treated Patients

By

Investigators report on the efficacy of a structured prophylactic regimen of loperamide for 2 cycles to reduce incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer, at SABCS 2016.

PAM50 HER2-E Subtype Predicts pCR Following Lapatinib, Trastuzumab

PAM50 HER2-E Subtype Predicts pCR Following Lapatinib, Trastuzumab

By

In this presentation at SABCS 2016, researchers present an evaluation of the ability of the PAM50 HER2-enriched intrinsic subtype to predict pathologic complete response in the breast in patients who received 18 weeks of neoadjuvant dual HER2 blockade.

Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC

Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC

By

In a poster presentation at SABCS 2016, researchers reported on the efficacy and safety of netupitant/palonosetron (NEPA) for the prevention of CINV in patients receiving highly or moderately emetogenic chemotherapy.

Arsenic Pretreatment May Protect Normal Tissue During Chemo in Breast Cancer

Arsenic Pretreatment May Protect Normal Tissue During Chemo in Breast Cancer

By

Researchers found that temporary pretreatment with LDA may protect normal breast tissue during chemotherapy for breast cancer in patients undergoing breast-conserving therapy, according to a study presented at SABCS 2016.

Omitting RT in Certain Older Women With Early Breast Cancer is Safe

Omitting RT in Certain Older Women With Early Breast Cancer is Safe

By

Researchers report their study findings on the safety of omitting radiotherapy after breast-conserving surgery, sentinel node biopsy, and adjuvant endocrine therapy in older patients with early breast cancer and favorable histopathology at SABCS 2016.

Assessment of Stromal Features in DCIS Requires Robustness

Assessment of Stromal Features in DCIS Requires Robustness

By

Robustness of dichotomous assessment is important when evaluating stromal features of ductal carcinoma in situ (DCIS), according to a study presented at SABCS 2016.

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

By

The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.

CT-Based Technique for Body Mass Measurements of Patients With Cancer Improves Disease Staging, Therapy Monitoring

CT-Based Technique for Body Mass Measurements of Patients With Cancer Improves Disease Staging, Therapy Monitoring

By

A new method of measuring lean body mass accounts for changes in body composition, enabling improved disease staging and monitoring of therapy.

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

By

Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.

Premedication With Antiemetic Improves Length of Stay and Readmissions for a Liver Cancer Procedure

By

Including an antiemetic in the preprocedure medications for patients with liver cancer undergoing drug eluting bead chemoembolization (DEB TACE) can shorten hospital stays and reduce the chance for readmission due to complications.

Imaging Technique Is Predictive of Immunotherapy Response in Non-Small Cell Lung Cancer

Imaging Technique Is Predictive of Immunotherapy Response in Non-Small Cell Lung Cancer

By

Results from phase II trial on the use of FDG-PET to evaluate the efficacy of an immunotherapy drug in the treatment of NSCLC.

Intensive Protocol Improves Survival for Adults with Acute Lymphoblastic Leukemia

Intensive Protocol Improves Survival for Adults with Acute Lymphoblastic Leukemia

By

Event-free survival for adult patients with ALL has improved from 40% to 73% with the implementation of the NOPHO ALL 2008 protocol in July 2008.

High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML

High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML

By

Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).

Blinatumomab Improves Overall Survival in Acute Lymphoblastic Leukemia

By

Overall survival for patients with acute lymphoblastic leukemia (ALL) was nearly doubled to 7.8 months from 4.0 months by treating patients with blinatumomab compared with standard of care.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs